The addition of CD20 monoclonal antibodies to lenalidomide improves response rates and survival in relapsed/refractory patients with chronic lymphocytic leukaemia relative to lenalidomide monotherapy - the MD Anderson Cancer Center experience

Philip A. Thompson, Uri Rozovski, Michael J. Keating, Francesco Stingo, Susan C. Smith, William G. Wierda, Lorenzo Falchi, Susan M. O'Brien, Zeev Estrov, Jan A. Burger, Alessandra Ferrajoli

Research output: Contribution to journalLetterpeer-review

4 Scopus citations
Original languageEnglish (US)
Pages (from-to)281-284
Number of pages4
JournalBritish Journal of Haematology
Volume171
Issue number2
DOIs
StatePublished - Oct 1 2015

Keywords

  • CD20 monoclonal antibodies
  • Chronic lymphocytic leukaemia
  • Lenalidomide
  • Relapsed/refractory

ASJC Scopus subject areas

  • Hematology

Cite this